NEW YORK, NY / ACCESSWIRE / August 3, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (OTCQB: PBIO).

"We see PBIO as a speculative growth investment in the healthcare sector with what appears to be building momentum for its highly differentiated pressure cycling technology, or PCT, products and services. With expectations for revenue to rise from $1.37mn in 2014 to surpass $2mn in 2015, Pressure BioSciences is clearly still in the early stages of a growth cycle with long potential as it pursues the $6bn market for life sciences sample preparation," stated Ajay Tandon, CEO of SeeThruEquity. "In conjunction with this momentum is the recent private placement. PBIO will issue senior secured convertible debentures with a fixed conversion price of $0.28 per restricted common share, and common stock purchase warrants exercisable into a total of 3.89mn shares of restricted common stock at an exercise price of $0.40 per share. This appears to be a very fair deal, to both investors and the company. We maintain our price target of $1.57 per share for PBIO."

The report is available here: PBIO August Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Additional highlights from the update note are as follows:

New studies point to broad applicability for PCT technology

We have been encouraged by press releases in the last two months highlighting the applicability of PCT as a key tool in drug discovery and cancer detection, which enhances the company's growth prospects, in our view. In July, PCT was noted as a key sample preparation technology in an article analyzing the importance of the early detection of diabetes in internationally recognized journal Biochimica et Biophysica Acta. The PCT platform was also highlighted in June as a key component in a new process for identifying novel protein biomarker candidates for more precise classification of prostate cancer by the world renowned Institute of Molecular Systems Biology, ETH Zurich. Importantly, PCT was also featured as a key technology for two new potential applications with the potential to expand its market opportunity ? testing soil quality and as a better method for extracting DNA from rape kits and other forensic samples.

2015 a potential watershed year for PBIO

We see 2015 as a potential watershed year for PBIO. With a seasoned management team led by former Boston Biomedica and Panacos Pharmaceuticals Founder and CEO Richard T. Schumacher, PBIO has attracted an impressive initial group of 150 customers, including Amgen, Merck, Monsanto, Biogen, UCLA, Stanford, Harvard, FDA, NIH, USDA, and the CDC, among others. Having raised capital to fund growth in the short run, PBIO is now focused on ramping sales and commercialization efforts with these and many new customers for its new PCT systems: 1) the next generation high throughput Barozyme HT48; 2) the first of its kind HUB880 Ultra-High Pressure Generator, and 3) the new uPestle consumable.

With product development complete and fundraising in place to invest in sales growth, we see the next twelve months as having potential for significant growth for the company. Indeed, management has guided for revenue to surpass $2mn in 2015, with sales of products and services expected to accelerate into the end of the year. We have forecast revenue of $2.2mn for PBIO in 2015E, which implies annual top line growth of 60%.

PBIO closes first tranche of $5mn private placement

On July 23, 2015, PBIO announced that it raised $2.18mn in gross proceeds, as the company closed on the first tranche of its recently announced $5mn private placement. Of the $2.18mn, $1.52mn was in the form of cash, and the $0.66mn resulted from the conversion of principal and interest from promissory notes.

We expect the company to use the proceeds to invest in growing its sales and marketing efforts as the company is in the process of commercializing several attractive new product lines including: 1) the next generation high throughput Barozyme HT48; 2) the first of its kind HUB880 Ultra-High Pressure Generator, and 3) the new uPestle consumable.

In conjunction with the private placement, PBIO will issue Senior Secured Convertible Debentures with a fixed conversion price of $0.28 per restricted common share, and Common Stock Purchase Warrants exercisable into a total of 3.89mn shares of restricted common stock at an exercise price of $0.40 per share.

Please review important disclosures on our website at www.seethruequity.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity